PMID- 29630956
OWN - NLM
STAT- MEDLINE
DCOM- 20190103
LR  - 20190103
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 117
DP  - 2018 Jul
TI  - Mirabegron 25 mg Monotherapy Is Safe but Less Effective in Male Patients With 
      Overactive Bladder and Bladder Outlet Obstruction.
PG  - 115-119
LID - S0090-4295(18)30295-4 [pii]
LID - 10.1016/j.urology.2018.03.038 [doi]
AB  - OBJECTIVE: To compare the therapeutic efficacy and safety of mirabegron 
      monotherapy in male patients with overactive bladder (OAB) with and without 
      bladder outlet obstruction (BOO). MATERIALS AND METHODS: Male patients with OAB 
      aged >/=20 years, with or without BOO, receiving mirabegron 25 mg monotherapy once 
      daily, were prospectively enrolled. The treatment results were assessed using 
      global response assessment, international prostate symptom score and subscores, 
      overactive bladder symptom score, patient perception on intensity of urgency 
      scale, patient perception of bladder condition, and quality of life index at 1 
      and 3 months after treatment. RESULTS: Of the 289 enrolled patients (mean age, 
      71.2 years), 207 did not have BOO (71.6%) and 82 had BOO (28.4%). The baseline 
      OAB symptoms were similar between patients with and without BOO. After mirabegron 
      treatment, the satisfactory rate (global response assessment score >==1) were 
      similar between those without BOO (61.3%) and with BOO (57.1%). The improvement 
      of quality of life index and patient perception of bladder condition was also 
      found in both groups. However, only patients without BOO had significantly 
      improved international prostate symptom score and subscores, overactive bladder 
      symptom score, and patient perception on intensity of urgency scale. Although 
      most adverse events (AEs) were mild, patients with BOO had significantly higher 
      AEs rate (18.6%) than those without BOO (8.2%, P = .026). CONCLUSION: Mirabegron 
      monotherapy in male patients with OAB and BOO was safe. However, the storage 
      symptoms improvement was less in patients with BOO and AEs rate was higher.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Liao, Chun-Hou
AU  - Liao CH
AD  - Department of Urology, Cardinal Tien Hospital and Fu-Jen Catholic University, New 
      Taipei, Taiwan.
FAU - Kuo, Hann-Chorng
AU  - Kuo HC
AD  - Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, 
      Hualien, Taiwan. Electronic address: hck@tzuchi.com.tw.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20180406
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Acetanilides)
RN  - 0 (Adrenergic beta-3 Receptor Agonists)
RN  - 0 (Thiazoles)
RN  - MVR3JL3B2V (mirabegron)
SB  - IM
MH  - Acetanilides/administration & dosage/adverse effects/*therapeutic use
MH  - Adrenergic beta-3 Receptor Agonists/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Aged
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Prospective Studies
MH  - Quality of Life
MH  - Severity of Illness Index
MH  - Thiazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Urinary Bladder Neck Obstruction/complications/*drug therapy
MH  - Urinary Bladder, Overactive/complications/*drug therapy/physiopathology
EDAT- 2018/04/10 06:00
MHDA- 2019/01/04 06:00
CRDT- 2018/04/10 06:00
PHST- 2017/10/31 00:00 [received]
PHST- 2018/01/02 00:00 [revised]
PHST- 2018/03/22 00:00 [accepted]
PHST- 2018/04/10 06:00 [pubmed]
PHST- 2019/01/04 06:00 [medline]
PHST- 2018/04/10 06:00 [entrez]
AID - S0090-4295(18)30295-4 [pii]
AID - 10.1016/j.urology.2018.03.038 [doi]
PST - ppublish
SO  - Urology. 2018 Jul;117:115-119. doi: 10.1016/j.urology.2018.03.038. Epub 2018 Apr 
      6.